{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:47:18Z","timestamp":1761745638045,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kafr El Shiekh University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Previous studies have shown that Trimetazidine (TMZ) improves vascular endothelial function and reduces the inflammatory process progression. However, limited data have been available regarding its effects on myocardial fibrosis following ischemia and causing left ventricular dysfunction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To investigate the impact of TMZ adjuvant therapy for ischemic cardiomyopathy (ICM) on cardiac fibrosis, vascular endothelial function, inflammation, and myocardial functions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This randomized, double-blind controlled clinical trial included 48 patients (aged 59.4 \u00b1 9 years) with ICM who were randomly assigned to two groups: TMZ 35 mg twice daily and placebo in addition to conventional ICM medications. All patients received the tablets for 3 months. Both groups were then compared in terms of connective tissue growth factor (CTGF), endothelin-1 (ET-1), tumor necrosis factor-alpha (TNF-\u03b1), and some echocardiographic indices, weekly angina attacks and nitrate consumption before and after treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No significant differences between CTGF, ET-1, and TNF-\u03b1 levels, in addition to some echocardiographic indices, were observed between both groups before treatment. After treatment, the TMZ group had significantly lower ET-1 than the placebo group, with both groups exhibiting a substantial decrease in TNF-\u03b1 and CTGF. The TMZ group had lower mean \u00b1 SD levels for TNF-\u03b1 and CTGF and showed significant improvement in echocardiographic indices and weekly angina attacks after treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Adjunctive TMZ therapy for ICM effectively improved vascular endothelial function and reduced inflammation. Furthermore, our exploratory findings may be used to provide new information on the potential effects of TMZ on myocardial fibrosis by downregulating CTGF.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10557-022-07340-0","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T22:02:22Z","timestamp":1652220142000},"page":"955-964","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The Impact of Trimetazidine on Cardiac Fibrosis, Inflammation, and Function in Ischemic Cardiomyopathy Patients"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3303-0399","authenticated-orcid":false,"given":"Noha M.","family":"El-khodary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asser I.","family":"Ghoneim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed A.","family":"El-tayaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman M.","family":"El-touny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"7340_CR1","doi-asserted-by":"publisher","first-page":"16812","DOI":"10.1002\/jcp.28350","volume":"234","author":"AK Malakar","year":"2019","unstructured":"Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234:16812\u201323.","journal-title":"J Cell Physiol."},{"key":"7340_CR2","unstructured":"Bhandari B, Rodriguez BSQ, Masood W. Ischemic cardiomyopathy. In: StatPearls [Internet]. Treasure Island: StatPearls; 2020."},{"key":"7340_CR3","doi-asserted-by":"publisher","first-page":"e006006","DOI":"10.1161\/CIRCHEARTFAILURE.119.006006","volume":"12","author":"M Sekulic","year":"2019","unstructured":"Sekulic M, Zacharias M, Medalion B. Ischemic cardiomyopathy and heart failure: consideration for fibromuscular dysplasia with intimal fibroplasia of coronary arteries. Circ Heart Fail. 2019;12:e006006.","journal-title":"Circ Heart Fail."},{"key":"7340_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.amjcard.2006.07.005","volume":"98","author":"V Bertomeu-Gonzalez","year":"2006","unstructured":"Bertomeu-Gonzalez V, Bouzas-Mosquera A, Kaski JC. Role of trimetazidine in management of ischemic cardiomyopathy. Am J Cardiol. 2006;98:19\u201324.","journal-title":"Am J Cardiol."},{"key":"7340_CR5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ihj.2016.03.021","volume":"68","author":"A Momen","year":"2016","unstructured":"Momen A, Ali M, Karmakar PK, et al. Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy - six months follow-up result. Indian Heart J. 2016;68:809\u201315.","journal-title":"Indian Heart J."},{"key":"7340_CR6","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s40265-014-0233-5","volume":"74","author":"P Chrusciel","year":"2014","unstructured":"Chrusciel P, Rysz J, Banach M. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. Drugs. 2014;74:971\u201380.","journal-title":"Drugs."},{"key":"7340_CR7","unstructured":"Mann DL. Heart failure: a companion to Braunwald\u2019s heart disease E-book 2nd ed: Elsevier Health Sciences; 2010."},{"key":"7340_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/ehjcvp\/pvv051","volume":"2","author":"CP McCarthy","year":"2016","unstructured":"McCarthy CP, Mullins KV, Kerins DM. The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent. Eur Heart J Cardiovasc Pharmacother. 2016;2:266\u201372.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"7340_CR9","unstructured":"Fragasso G, Anastasia G, Monaca G, Pinto G. Clinical benefits of targeting cardiac cells directly with trimetazidine in patients with coronary disease and diabetes. Heart Metab.\u00a02017;73:24\u20138."},{"key":"7340_CR10","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1097\/MJT.0000000000000180","volume":"23","author":"CA D\u00e9zsi","year":"2016","unstructured":"D\u00e9zsi CA. Trimetazidine in practice: review of the clinical and experimental evidence. Am J Ther. 2016;23:e871\u20139.","journal-title":"Am J Ther."},{"issue":"5","key":"7340_CR11","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.14336\/AD.2020.0604","volume":"11","author":"Y Ding","year":"2020","unstructured":"Ding Y, Wang Y, Zhang W, et al. Roles of biomarkers in myocardial fibrosis. Aging Dis. 2020;11(5):1157\u201374.","journal-title":"Aging Dis."},{"key":"7340_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/cvr\/cvq181","volume":"88","author":"X Liu","year":"2010","unstructured":"Liu X, Gai Y, Liu F, et al. Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase\u2013ROS\u2013CTGF pathway. Cardiovasc Res. 2010;88:150\u20138.","journal-title":"Cardiovasc Res."},{"key":"7340_CR13","first-page":"1477","volume":"18","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Li S, Quan E, et al. Trimetazidine inhibits cardiac fibrosis by reducing reactive oxygen species and downregulating connective tissue growth factor in streptozotocin-induced diabetic rats. Exp Ther Med. 2019;18:1477\u201385.","journal-title":"Exp Ther Med."},{"key":"7340_CR14","doi-asserted-by":"publisher","first-page":"593269","DOI":"10.3389\/fcell.2020.593269","volume":"8","author":"Z Chen","year":"2020","unstructured":"Chen Z, Zhang N, Zhang Z, Zhang G, Zhang B. Connective tissue growth factor: from molecular understandings to drug discovery. Front Cell Dev Biol. 2020;8:593269.","journal-title":"Front Cell Dev Biol."},{"key":"7340_CR15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407\u201377 Erratum in: Eur Heart J. 2020;41:4242.","journal-title":"Eur Heart J"},{"key":"7340_CR16","unstructured":"Kosaraju A, Goyal A, Grigorova Y, Makaryus AN. Left ventricular ejection fraction. In: StatPearls. StatPearls Publishing; 2017."},{"key":"7340_CR17","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0002-8703(03)00415-0","volume":"146","author":"G Fragasso","year":"2003","unstructured":"Fragasso G, Piatti P, Monti L, et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003;146:854.","journal-title":"Am Heart J."},{"key":"7340_CR18","doi-asserted-by":"publisher","first-page":"e13580","DOI":"10.1097\/MD.0000000000013580","volume":"97","author":"J Wen","year":"2018","unstructured":"Wen J, Ma X, Zhang L, et al. Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: a systematic review and meta-analysis. Medicine. 2018;97:e13580.","journal-title":"Medicine."},{"key":"7340_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.7793\/jcoron.19.13-00003","volume":"19","author":"T Isomura","year":"2013","unstructured":"Isomura T, Hirota M, Hoshino J, et al. Strategy of treatment for ischemic cardiomyopathy. J Jpn Coron Assoc. 2013;19:339\u201346.","journal-title":"J Jpn Coron Assoc."},{"key":"7340_CR20","doi-asserted-by":"publisher","unstructured":"Mentz RJ, Broderick S, Shaw LK, Chiswell K, Fiuzat M, O\u2019Connor CM. Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events. Eur J Heart Fail. 2014;16:854\u201360. https:\/\/doi.org\/10.1002\/ejhf.130.","DOI":"10.1002\/ejhf.130"},{"key":"7340_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.lfs.2012.03.015","volume":"92","author":"P Zhao","year":"2013","unstructured":"Zhao P, Zhang J, Yin X-G, et al. The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy. Life Sci. 2013;92:633\u20138.","journal-title":"Life Sci."},{"key":"7340_CR22","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/FJC.0b013e31817bdd66","volume":"51","author":"R Belardinelli","year":"2008","unstructured":"Belardinelli R, Cianci G, Gigli M, Mazzanti M, Lacalaprice F. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. J Cardiovasc Pharmacol. 2008;51:611\u20135.","journal-title":"J Cardiovasc Pharmacol."},{"key":"7340_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/clc.20888","volume":"34","author":"B Hu","year":"2011","unstructured":"Hu B, Li W, Xu T, Chen T, Guo J. Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: A meta-analysis of randomized, controlled trials. Clin Cardiol. 2011;34:395\u2013400.","journal-title":"Clin Cardiol."},{"key":"7340_CR24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jacc.2011.11.027","volume":"59","author":"L Zhang","year":"2012","unstructured":"Zhang L, Lu Y, Jiang H, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol. 2012;59:913\u201322.","journal-title":"J Am Coll Cardiol."},{"key":"7340_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/FJC.0b013e31814fa9cb","volume":"50","author":"P Di Napoli","year":"2007","unstructured":"Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsotti A. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d\u2019Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol. 2007;50:585\u20139.","journal-title":"J Cardiovasc Pharmacol."},{"key":"7340_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2165\/00129784-200505040-00006","volume":"5","author":"T El-Kady","year":"2005","unstructured":"El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs. 2005;5:271\u20138.","journal-title":"Am J Cardiovasc Drugs."},{"key":"7340_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijcard.2020.04.074","volume":"314","author":"M Marzilli","year":"2020","unstructured":"Marzilli M, Crea F, Morrone D, et al. Myocardial ischemia: from disease to syndrome. Int J Cardiol. 2020;314:32\u20135.","journal-title":"Int J Cardiol."},{"key":"7340_CR28","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/eurheartj\/eht513","volume":"35","author":"F Crea","year":"2014","unstructured":"Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. Eur Heart J. 2014;35:1101\u201311.","journal-title":"Eur Heart J."},{"key":"7340_CR29","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1111\/bph.12475","volume":"171","author":"N Fillmore","year":"2014","unstructured":"Fillmore N, Mori J, Lopaschuk GD. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol. 2014;171:2080\u201390.","journal-title":"Br J Pharmacol."},{"key":"7340_CR30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.biochi.2015.02.020","volume":"112","author":"T Martins-Marques","year":"2015","unstructured":"Martins-Marques T, Catarino S, Marques C, et al. Heart ischemia results in connexin43 ubiquitination localized at the intercalated discs. Biochimie. 2015;112:196\u2013201.","journal-title":"Biochimie."},{"key":"7340_CR31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ijcard.2012.09.123","volume":"163","author":"G Fragasso","year":"2013","unstructured":"Fragasso G, Rosano G, Baek SH, et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int J Cardiol. 2013;163:320\u20135.","journal-title":"Int J Cardiol."},{"key":"7340_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00045391-200501000-00006","volume":"12","author":"EI Chazov","year":"2005","unstructured":"Chazov EI, Lepakchin VK, Zharova EA, et al. Trimetazidine in Angina Combination Therapy--the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther. 2005;12:35\u201342.","journal-title":"Am J Ther."},{"key":"7340_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ijcard.2019.05.063","volume":"293","author":"M Marzilli","year":"2019","unstructured":"Marzilli M, Vinereanu D, Lopaschuk G, et al. Trimetazidine in cardiovascular medicine. Int J Cardiol. 2019;293:39\u201344.","journal-title":"Int J Cardiol."},{"key":"7340_CR34","doi-asserted-by":"crossref","unstructured":"Iskesen I, Kurdal AT, Eserdag M, Cerrahoglu M, Sirin BH, editors. Trimetazidine may protect the myocardium during cardiac surgery. Heart Surg Forum. 2009;12:E175\u20139.","DOI":"10.1532\/HSF98.20081133"},{"key":"7340_CR35","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/bph.13454","volume":"173","author":"M Cavar","year":"2016","unstructured":"Cavar M, Ljubkovic M, Bulat C, et al. Trimetazidine does not alter metabolic substrate oxidation in cardiac mitochondria of target patient population. Br J Pharmacol. 2016;173:1529\u201340.","journal-title":"Br J Pharmacol."},{"key":"7340_CR36","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/2047487315588391","volume":"23","author":"M Sandri","year":"2016","unstructured":"Sandri M, Viehmann M, Adams V, et al. Chronic heart failure and aging\u2013effects of exercise training on endothelial function and mechanisms of endothelial regeneration: results from the Leipzig exercise intervention in chronic heart failure and aging (LEICA) study. Eur J Prev Cardiol. 2016;23:349\u201358.","journal-title":"Eur J Prev Cardiol."},{"key":"7340_CR37","doi-asserted-by":"publisher","first-page":"e0174119","DOI":"10.1371\/journal.pone.0174119","volume":"12","author":"GF Skovsted","year":"2017","unstructured":"Skovsted GF, Kruse LS, Berchtold LA, Grell A-S, Warfvinge K, Edvinsson L. Myocardial ischemia-reperfusion enhances transcriptional expression of endothelin-1 and vasoconstrictor ETB receptors via the protein kinase MEK-ERK1\/2 signaling pathway in rat. PLoS One. 2017;12:e0174119.","journal-title":"PLoS One."},{"key":"7340_CR38","doi-asserted-by":"publisher","first-page":"E54","DOI":"10.1152\/ajpendo.00083.2005","volume":"290","author":"LD Monti","year":"2006","unstructured":"Monti LD, Setola E, Fragasso G, et al. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy. Am J Physiol Endocrinol. 2006;290:E54\u20139.","journal-title":"Am J Physiol Endocrinol."},{"key":"7340_CR39","doi-asserted-by":"publisher","first-page":"e40424","DOI":"10.1371\/journal.pone.0040424","volume":"7","author":"X Zhou","year":"2012","unstructured":"Zhou X, Li C, Xu W, Chen J. Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammation. PloS One. 2012;7:e40424.","journal-title":"PloS One."},{"key":"7340_CR40","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12872-020-01557-3","volume":"20","author":"L Wu","year":"2020","unstructured":"Wu L, Luan Y, Li Y, et al. Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial. BMC Cardiovasc Disord. 2020;20:273.","journal-title":"BMC Cardiovasc Disord."},{"key":"7340_CR41","first-page":"33","volume":"88","author":"SG Kanorskii","year":"2016","unstructured":"Kanorskii SG, Smolenskaya NV. Triple antianginal combinations in the treatment of elderly and senile patients with stable angina. Ter Arkh. 2016;88:33\u201340.","journal-title":"Ter Arkh"},{"key":"7340_CR42","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ihj.2016.04.023","volume":"68","author":"S Jatain","year":"2016","unstructured":"Jatain S, Kapoor A, Sinha A, et al. Metabolic manipulation in dilated cardiomyopathy: assessing the role of trimetazidine. Indian Heart J. 2016;68:803\u20138.","journal-title":"Indian Heart J."}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07340-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-022-07340-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07340-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T08:08:20Z","timestamp":1695370100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-022-07340-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["7340"],"URL":"https:\/\/doi.org\/10.1007\/s10557-022-07340-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2022,5,10]]},"assertion":[{"value":"25 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Research Ethics Committee of Faculty of Pharmacy, Damanhour University (No: 1218PP9).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written informed consent before enrollment in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}